References
- 1Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019 Sep; 33(9): 905–918. DOI: 10.1007/s40263-019-00661-z. PMID: 31473980; PMCID: PMC6776563.
- 2Ganesalingam J, Bain P. Apomorphine-induced necrotic ulcers. Mov Disord. 2011 Oct; 26(12): 2182. DOI: 10.1002/mds.23832. Epub 2011 Sep 28. PMID: 21956252.
- 3Skorvanek M, Bhatia KP. The Skin and Parkinson’s Disease: Review of Clinical, Diagnostic, and Therapeutic Issues. Mov Disord Clin Pract. 2017; 4: 21–31. DOI: 10.1002/mdc3.12425
